Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients with Failure of Lamivudine and Adefovir Combination

Clinical Therapeutics

Volumn 37, Issue 7, 2015, Pages 1433-1442

  Park, Jae Ho ^a   Jung, Seok Won ^a   Park, Neung Hwa ^a   Park, Bo Ryung ^a   Kim, Min Ho ^a   Kim, Chang Jae ^a   Lee, Byung Uk ^a   Jeong, In Du ^a   Kim, Byung Gyu ^a   Bang, Sung Jo ^a   Shin, Jung Woo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

chronic hepatitis B; Key words adefovir resistance; lamivudine resistance; tenofovir

Indexed keywords

ADEFOVIR; LAMIVUDINE; TENOFOVIR; ADENINE; ANTIVIRUS AGENT; PHOSPHONIC ACID DERIVATIVE;

ARTICLE; CHRONIC HEPATITIS B; ADULT; AGED; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; COMBINATION DRUG THERAPY; FEMALE; HEPATITIS B, CHRONIC; HUMAN; MALE; MIDDLE AGED; RETREATMENT; TIME FACTOR; TREATMENT OUTCOME;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RETREATMENT; TENOFOVIR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84946173044     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.04.007     Document Type: Article

References (25)

1. A.S. Lok, C.L. Lai, N. Leung, and et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 2003 1714 1722
2. M.F. Yuen, E. Sablon, C.K. Hui, and et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy Hepatology 34 2001 785 791
3. M.G. Peters, Hw Hann Hw, P. Martin, and et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B Gastroenterology 126 2004 91 101
4. R. Perrillo, H.W. Hann, D. Mutimer, and et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus Gastroenterology 126 2004 81 90
5. J. Fung, C.L. Lai, J.C. Yuen, and et al. Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population Antivir Ther 12 2007 41 46
6. I. Rapti, E. Dimou, P. Mitsoula, and S.J. Hadziyannis Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B Hepatology 45 2007 307 313
7. P. Lampertico, M. Vigano, E. Manenti, and et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine Hepatology 42 2005 1414 1419
8. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
9. R.P. Perrillo, H.W. Hann, E. Schiff, and et al. Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance Hepatol Int 5 2011 654 663
10. P. Lampertico, M. Vigano, E. Manenti, and et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients Gastroenterology 133 2007 1445 1451
11. H.J. Ryu, J.M. Lee, S.H. Ahn, and et al. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B J Med Virol 82 2010 1835 1842
12. W.K. Seto, K. Liu, J. Fung, and et al. Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir Antivir Ther 17 2012 1255 1262
13. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
14. F. van Bommel, R.A. de Man, H. Wedemeyer, and et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues Hepatology 51 2010 73 80
15. F. van Bommel, B. Zollner, C. Sarrazin, and et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy Hepatology 44 2006 318 325
16. S.J. Patterson, J. George, S.I. Strasser, and et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B Gut 60 2011 247 254
17. T. Berg, P. Marcellin, F. Zoulim, and et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection Gastroenterology 139 2010 1207 1217
18. J.W. Shin, S.W. Jung, B.R. Park, and et al. HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance Antivir Ther 17 2012 387 394
19. R. Zoutendijk, J.G. Reijnders, A. Brown, and et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response Hepatology 54 2011 443 451
20. M.F. Yuen, W.K. Seto, J. Fung, and et al. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety Am J Gastroenterol 106 2011 1264 1271
21. A. Ono, F. Suzuki, Y. Kawamura, and et al. Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients J Hepatol 57 2012 508 514
22. J.W. Shin, S.W. Jung, B.R. Park, and et al. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels J Viral Hepat 19 2012 724 731
23. T. Berg, F. Zoulim, B. Moeller, and et al. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients J Hepatol 60 2014 715 722
24. X. Qi, S. Xiong, H. Yang, and et al. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents Antivir Ther 12 2007 355 362
25. E.S. Svarovskaia, M. Curtis, Y. Zhu, and et al. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen J Viral Hepat 20 2013 131 140